DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients

Author： Nogueira Augusto   Assis Joana   Catarino Raquel   Medeiros Rui  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.6, 2013-04, pp. : 689-700

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Emerging drugs for non-small-cell lung cancer

By Felip Enriqueta   Santarpia Mariacarmela   Rosell Rafael  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 3, 2007-09 ,pp. : 449-460

Informa Healthcare

Access to resources Recommend Favorite

Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer

By  

Current Medicinal Chemistry, Vol. 19, Iss. 22, 2012-08 ,pp. : 3689-3700

Bentham Science Publishers

Access to resources Recommend Favorite

Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non–small cell lung cancer

By NiJun   LiuDong-Yang   HuBei   LiChen   JiangJi   WangHan-Ping   ZhangLi  

Cancer, Vol. 121, Iss. 17, 2015-09 ,pp. : 3146-3156

Blackwell Publishing

Access to resources Recommend Favorite

The Role of Pemetrexed Combined with Gemcitabine for Non-Small-Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 61-66

Bentham Science Publishers

Access to resources Recommend Favorite

Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 78-84

Bentham Science Publishers

Access to resources Recommend Favorite